Skip to main content

Robert Siliciano is interested in devising strategies for eradicating the latent reservoir of HIV-1 in infected patients and developing improved therapies for HIV-1 infection. Siliciano and his team use experimental and computational approaches in their work, which ranges from evaluating drugs that target the latent reservoir and developing assays to monitor the elimination of this reservoir during clinical trials, to uncovering the pharmacodynamic principles underlying antiretroviral drugs and how to prevent drug resistance. They are also studying the immunology of HIV-1 infection, particularly the ability of some patients to control the infection without antiretroviral therapy.Robert Siliciano is interested in devising strategies for eradicating the latent reservoir of HIV-1 in infected patients and developing improved therapies for HIV-1 infection. Siliciano and his team use experimental and computational approaches in their work, which ranges from evaluating drugs that target the latent reservoir and developing assays to monitor the elimination of this reservoir during clinical trials, to uncovering the pharmacodynamic principles underlying antiretroviral drugs and how to prevent drug resistance. They are also studying the immunology of HIV-1 infection, particularly the ability of some patients to control the infection without antiretroviral therapy.